Share on StockTwits

Conatus Pharmaceuticals (NASDAQ:CNAT) posted its quarterly earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.01, Stock Ratings Network.com reports.

Conatus Pharmaceuticals (NASDAQ:CNAT) traded down 2.38% on Tuesday, hitting $5.34. 315,008 shares of the company’s stock traded hands. Conatus Pharmaceuticals has a one year low of $5.27 and a one year high of $15.67. The stock has a 50-day moving average of $6.9 and a 200-day moving average of $8.54. The company’s market cap is $83.5 million.

CNAT has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus cut their price target on shares of Conatus Pharmaceuticals from $16.00 to $14.00 in a research note on Friday, March 28th. Analysts at Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Friday, March 7th. They set a “buy” rating on the stock. Four equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $14.00.

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of medicines to treat liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.